About OncoStem
OncoStem is a company based in Bengaluru (India) founded in 2011 by Manjiri Bakre. OncoStem has raised $9 million across 2 funding rounds from investors including Peak XV Partners and Artiman. The company has 17 employees. OncoStem operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Bengaluru, India
- Employees 17
- Founders Manjiri Bakre
- SectorsHealthcare
- Website oncostem.com
- Social LinkedIn YouTube
- Legal Name Oncostem Diagnostics Private Limited
- Date of Incorporation 15 Mar, 2011
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹10.02 Cr
FY 2025 · +40% YoY
- Net Profit₹3.71 Cr
FY 2025 · 37% margin
- EBITDA₹3.80 Cr
FY 2025 · 38% margin
- Total Equity Funding$9M (USD)
in 2 rounds
- Latest Funding Round$6M (USD), Series A
Sep 2017
- InvestorsPeak XV Partners
& 1 more
- Employee Count17
Associated legal entities of OncoStem
OncoStem operates through Oncostem Diagnostics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Oncostem Diagnostics Private Limited CIN U85110KA2011PTC057624 | Active | 15 Mar 2011 | Bangalore, Karnataka | ₹10.0 Cr | 17 | 2 | View details |
Apps and channels of OncoStem
its YouTube channel OncoStem Diagnostics has 2.21K subscribers and 30 videos.
Videos from OncoStem
The most watched videos on OncoStem's YouTube channel, OncoStem Diagnostics (2.21K subscribers). Click a video to play it here.
More on OncoStem Diagnostics.
Funding Insights of OncoStem
OncoStem has successfully raised a total of $9M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9M
- Total Rounds 2
- Last Round Series A — $6M
- First Round $3M
(Jun 2011)
- Investors Count 2
All 2 funding rounds of OncoStem with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $6M | Series A | – | Peak XV Partners | |
| Jun 2011 | $3M | Seed | – | Artiman | – |
2 investors in total: 2 institutional.
Investors in OncoStem
OncoStem has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Peak XV Partners and Artiman.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in technology and healthcare sectors. | 2000 | artiman.com | - | |
Venture capital firm investing in startups and providing support programs. | 2000 | peakxv.com | Bengaluru, India |
Investor details for OncoStem
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Oncostem Diagnostics Private Limited (OncoStem)
Oncostem Diagnostics Private Limited is the primary company behind OncoStem. The board of Oncostem Diagnostics Private Limited currently have 2 directors; the longest-serving is Manjiri Manohar Bakre, appointed in 2011. 9 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manjiri Manohar Bakre DIN 03035902 | Director | 17 Jun 2011 | 15 yrs 3 mo | Oncostem Diagnostics Private Limited |
| Thallam Satyanarayana DIN 02019355 | Director | 06 Apr 2022 | 4 yrs 6 mo | Oncostem Diagnostics Private Limited |
People of OncoStem
2 people are tracked at OncoStem (2 in leadership); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
| Founder & CEO | Leadership | |
| Executive Director | Leadership |
Complete people profiles for OncoStem
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of OncoStem
Figures of Oncostem Diagnostics Private Limited, the primary company behind OncoStem, for FY 2025. Revenue was ₹10.02 Cr (+40% year on year). Net profit was ₹3.71 Cr (37% margin). EBITDA was ₹3.80 Cr (38% margin). Revenue has grown at a compounded annual rate of -1% over three years and +6% over five years.
- ₹10.02 CrRevenue · FY 2025 · +40% YoY
- ₹3.71 CrNet profit · 37% margin
- ₹3.80 CrEBITDA · 38% margin
- ₹1 LakhPaid-up capital
- 17Employees (provident fund records)
- -1%Revenue CAGR, 3 years
- +6%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Oncostem Diagnostics Private Limited are on its company page.
Detailed financial statements for OncoStem
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of OncoStem
3 dated milestones of OncoStem across 6 years, from founding to its latest funding, stage changes and deals.
- Founded OncoStem is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series A, of $6.0M.
Competitors of OncoStem
OncoStem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| unitybiotechnology.com | 2016 | San Francisco, United States | $206M | – | Therapeutics for aging diseases are developed by targeting senescent cells. | |
| unilabs.com | 2000 | Geneva, Switzerland | – | – | Diagnostic services are provided through laboratories and radiology units. | |
| celsiustx.com | 2018 | Cambridge, United States | $148M | 50 | Single-cell RNA and genomic analysis for precision therapeutics are provided. | |
| intelliatx.com | 2014 | Cambridge, United States | $85.02M | 526 | Therapeutics using CRISPR/Cas9 are developed for various diseases. | |
| voyagertherapeutics.com | 2014 | Cambridge, United States | $105M | 183 | Gene Therapy to treat CNS diseases such as Parkinson’s disease, ALS. |
Detailed competitors of OncoStem
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncostem
Complete news archive for OncoStem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OncoStem
10 companies that operate in the same segment as OncoStem (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OncoStem
OncoStem was founded in 2011.
OncoStem is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Manjiri Bakre is the current CEO of OncoStem. They have also founded this company.
OncoStem is a funded company, having raised a total of $9M across 2 funding rounds to date. The company's 1st funding round was a Seed of $3M, raised on Jun 2011.
OncoStem has 17 employees.
The primary company behind OncoStem, Oncostem Diagnostics Private Limited, reported revenue of ₹10.02 Cr for FY 2025, up 40% year on year.
OncoStem was founded in 2011 in Bengaluru, India, and operates in the oncology diagnostics sector. Prognostic tests for cancer are developed, with the flagship product CanAssist-Breast employing an AI-based statistical model to assess breast cancer recurrence risk. Additional tumor details are provided to support customized treatment decisions. The company focuses on enhancing clinical outcomes through precise risk stratification.
OncoStem's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
OncoStem has 2 investors. Key investors include Peak XV Partners, and Artiman.
OncoStem operates through Oncostem Diagnostics Private Limited.
The legal entities of OncoStem currently have 2 directors, including Manjiri Manohar Bakre, Thallam Satyanarayana.